High-affinity binding to gas6

Patent metadata

Field	Value
Publication number	US-2016266136-A1
Application number	US-201314910565-A
Country	US
Kind code	A1
Filing date	Dec 12, 2013
Priority date	Aug 30, 2013
Publication date	Sep 15, 2016
Grant date	—

Abstract

Compositions and methods are provided for measuring the amount of GAS6 in a sample. Also provided are compositions and methods related to high-affinity CAS6 inhibitor agents that induce a conformational change of GAS6 that stabilizes Helix A of GAS6.

First claim

1 . A method of measuring the amount of Gas6 in a sample, the method comprising:
(a) contacting a GAS6 capture reagent with a sample to produce a contacted sample, wherein the capture reagent is capable of binding to GAS6 polypeptide with increased affinity compared to wild-type AXL; and (b) measuring the amount of GAS6 polypeptide that is bound to the capture reagent.

2 . The method according to claim 1 , wherein the capture reagent is capable of binding to the major and minor AXL binding sites on a single GAS6.

3 . The method according to claim 1 , wherein the capture reagent is capable of inducing a conformational change of GAS6 that stabilizes of Helix A of GAS6.

4 . The method according to claim 3 , wherein the capture reagent is capable of causing a structural change of Helix A of GAS6 that stabilizes the bound conformation of the GAS6 through N-terminal capping of Helix A of GAS6.

5 . The method according to claim 1 , wherein the capture reagent is a variant AXL polypeptide comprising at least one amino acid modification relative to the wild-type AXL (SEQ ID NO: 1).

6 .- 8 . (canceled)

9 . The method according to claim 5 , wherein the variant AXL polypeptide has a set of amino acid substitution(s) of the wild-type AXL sequence (SEQ ID NO. 1) selected from the group consisting of 1) Gly32Ser, Asp87Gly, Val92Ala, and Gly127Arg, 2) Glu26Gly, Val79Met, Val92Ala, and Gly127Glu, 3) Asn33Ser, Ser74Asn, Asp87Gly, and Val92Ala, 4) Ala72Val, Ile97Arg, and His116Arg, 5) Gln78Glu, 6) Ala72Val, 7) Gln86Arg, Ile90Val, and Val92Ala, 8) Ala72Val, and Val92Asp, 9) Asp65Asn, and Asp87Gly, 10) Asp87Gly, and Val92Ala, 11) Glu27Lys, His61Tyr, Ala72Val, Asp88Asn, Val92Ala, and Thr98Ala, 12) Val92Ala, Gln109Arg, 13) Thr44Ala, Ala72Val, Ile90Val, Thr105Met, and Glu129Lys, 14) Val92Gly, 15) Val92Ala, Val112Ala, Phe113Leu, and Thr118Ala, 16) Val92Ala, and Thr98Pro, 17) Glu27Gly, and Asp87Gly, 18) Thr38Ile, and Val92Ala, 19) Asp87Gly, 20) Thr23Met, and Val92Ala, 21) Ala72Val, and Phe113Leu, 22) Gln86Arg, Val92Ala, 23) Ala19Thr, Glu26Gly, Glu27Gly, and Val92Ala, 24) Ile90Met and Val92Ala, 25) Gly32Ser, and Asp87Gly, 26) Gly32Ser, and Val92Ala, 27) Gly32Ser, and Gly127Arg, 28) Asp87Gly, and Gly127Arg, 29) Val92Ala, and Gly127Arg, 30) Asp87Gly, Val92Ala, and Gly127Arg, 31) Gly32Ser, Val92Ala, and Gly127Arg, 32) Gly32Ser, Asp87Gly, and Gly127Arg, 33) Gly32Ser, Asp87Gly, and Val92Ala and 34) Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg.

10 - 12 . (canceled)

13 . The method according to claim 5 , wherein the variant AXL variant polypeptide comprises at least one amino acid modification selected from the group consisting of 1) A19T, 2) T23M, 3) E26G, 4) E27G or E27K 5) G32S, 6) N33S, 7) T38I, 8) T44A, 9) H61Y, 10) D65N, 11) A72V, 12) S74N, 13) Q78E, 14) V79M, 15) Q86R, 16) D87G, 17) D88N, 18) I90M or I90V, 19) V92A, V92G or V92D, 20) I97R, 21) T98A or T98P, 22) T105M, 23) Q109R, 24) V112A, 25) F113L, 26) H116R, 27) T118A, 28) G127R or G127E, and 29) G129E and a combination thereof.

14 . The method according to claim 1 , wherein the capture reagent is immobilized.

15 . The method according to claim 14 , wherein the step of measuring comprises contacting the contacted sample with a detectable GAS6 binding agent.

16 . The method according to claim 15 , wherein the detectable GAS6 binding agent is an anti-GAS6 antibody.

17 . The method according to claim 16 , wherein the method is an enzyme-linked immunosorbent assay (ELISA).

18 . The method according to claim 1 , wherein the sample is a biological sample.

19 - 20 . (canceled)

21 . The method according to claim 18 , wherein the sample is obtained from an individual that has cancer or is suspected of having cancer.

22 . The method according to, wherein the individual is undergoing treatment comprising the administration of a GAS6 inhibitor claim 21 agent to the individual.

23 . The method according to claim 21 , wherein a prognosis and/or diagnosis is determined for the human based on the measured amount of GAS6

24 . The method according to claim 21 , wherein a prognosis or diagnosis is determined for the human based on the measured amount of GAS6 relative to:
(i) a known reference standard; and/or (ii) the amount of GAS6 measured from a reference sample.

25 . A method of determining the efficacy of a GAS6 inhibitor agent, the method comprising:
measuring the amount of GAS6 in a biological sample obtained from an individual undergoing treatment, wherein: (i) the treatment comprises the administration of a GAS6 inhibitor agent to the individual, and (ii) the measuring is performed according to the method of claim 1 .

26 . The method of claim 25 , further comprising, prior to the step of measuring, administering to the individual a GAS6 inhibitor agent that binds to GAS6 with higher affinity than wild type AXL (SEQ ID NO: 1).

27 . The method according to claim 25 , further comprising: determining a course of treatment based on the amount of GAS6 measured in the biological sample.

28 . (canceled)

29 . A GAS6 inhibitor agent that is capable of inducing a conformational change of GAS6 that stabilizes Helix A of GAS6, wherein the GAS6 inhibitor agent is capable of causing a structural change of Helix A of GAS6 that stabilizes the bound conformation of the GAS6 through N-terminal capping of Helix A of GAS6, and wherein the GAS6 inhibitor agent is not an AXL variant polypeptide comprising a Val92Ala mutation relative to wild type AXL (SEQ ID NO: 1).

30 - 33 . (canceled)

Assignees

• Univ Leland Stanford Junior

Inventors

• Cochran Jennifer R
• Giaccia Amato J
• Miao Yu
• Kariolis Mihalis
• Kapur Shiven
• Mathews Irimpan I

Classifications

• G01N33/575 Primary

  for cancer · CPC title

• G01N2500/20

  cell-free systems · CPC title

• G01N2800/7028

  Cancer · CPC title

• G01N33/6827 Primary

  Total protein determination, e.g. albumin in urine · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title